SELLAS Life Sciences Group (SELLAS Life Sciences Group) Debt-to-Equity : 0.08 (As of Mar. 2024)

View and export this data going back to 2008. Start your Free Trial

What is SELLAS Life Sciences Group Debt-to-Equity?

SELLAS Life Sciences Group's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $0.49 Mil. SELLAS Life Sciences Group's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $0.31 Mil. SELLAS Life Sciences Group's Total Stockholders Equity for the quarter that ended in Mar. 2024 was $9.68 Mil. SELLAS Life Sciences Group's debt to equity for the quarter that ended in Mar. 2024 was 0.08.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for SELLAS Life Sciences Group's Debt-to-Equity or its related term are showing as below:

SLS' s Debt-to-Equity Range Over the Past 10 Years
Min: -7.34 Med: 0.13 Max: 5.31
Current: 0.08

During the past 13 years, the highest Debt-to-Equity Ratio of SELLAS Life Sciences Group was 5.31. The lowest was -7.34. And the median was 0.13.

SLS's Debt-to-Equity is ranked better than
63.3% of 1068 companies
in the Biotechnology industry
Industry Median: 0.14 vs SLS: 0.08

SELLAS Life Sciences Group Debt-to-Equity Historical Data

The historical data trend for SELLAS Life Sciences Group's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

SELLAS Life Sciences Group Debt-to-Equity Chart

SELLAS Life Sciences Group Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

Get a 7-Day Free Trial

0.04

0.20

-0.11

SELLAS Life Sciences Group Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Debt-to-Equity	Get a 7-Day Free Trial															0.06	0.16	-0.17	-0.11	0.08

Competitive Comparison of SELLAS Life Sciences Group's Debt-to-Equity

For the Biotechnology subindustry, SELLAS Life Sciences Group's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

SELLAS Life Sciences Group's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, SELLAS Life Sciences Group's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where SELLAS Life Sciences Group's Debt-to-Equity falls into.

SELLAS Life Sciences Group Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

SELLAS Life Sciences Group's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.446	+	0.46)	/	-7.976
	=	-0.11

SELLAS Life Sciences Group's Debt to Equity Ratio for the quarter that ended in Mar. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.488	+	0.313)	/	9.684
	=	0.08

SELLAS Life Sciences Group (NAS:SLS) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

SELLAS Life Sciences Group Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of SELLAS Life Sciences Group's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

SELLAS Life Sciences Group (SELLAS Life Sciences Group) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » SELLAS Life Sciences Group Inc (NAS:SLS) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

RXK3:Germany

Address

7 Times Square, Suite 2503, New York, NY, USA, 10036

Website

https://www.sellaslifesciences.com

SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.

Executives

Angelos M. Stergiou	director, officer: President and CEO	C/O SELLAS LIFE SCIENCES GROUP, INC., 2000 CROW CANYON PLACE, SUITE 380, SAN RAMON CA 94583
Barbara A Wood	officer: EVP, Gen. Counsel, Corp. Sec.	58 S SERVICE RD, MELVILLE NY 11747
John Thomas Burns	officer: VP, Finance & Corp Controller	16760 SW UPPER BOONES FERRY RD, SUITE 101, PORTLAND X1 97224
Katherine Bach Kalin	director	3201 CARNEGIE AVENUE, CLEVELAND OH 44115
Robert Francomano	officer: Chief Commercial Officer	C/O STEMLINE THERAPEUTICS, INC., 750 LEXINGTON AVENUE, 11TH FLOOR, NEW YORK NY 10022
Nicholas J. Sarlis	officer: Chief Medical Officer and SVP	C/O SELLAS LIFE SCIENCES GROUP, INC., 2000 CROW CANYON PLACE, STE. 380, SAN RAMON CA 94583
Stephen F Ghiglieri	director	C/O NEUROGESX INC., 981 INDUSTRIAL ROAD SUITE F, SAN CARLOS CA 94070
Jane Wasman	director	C/O ACORDA THERAPEUTICS, INC., 420 SAW MILL RIVER ROAD, ARDSLEY NY 10502
David A Scheinberg	director	325 CENTRAL PARK W, APT 38, NEW YORK NY 10025
Van Nostrand Robert L	director	C/O ACHILLION PHARMACEUTICALS, INC., 300 GEORGE STREET, NEW HAVEN CT 06511
John Varian	director	ARYX THERAPEUTICS,INC., 6300 DUMBARTON CIRCLE, FREMONT CA 94555
Eqc Private Markets Sac Fund Ltd-eqc Biotech Sely Ii Fund`	10 percent owner	C/O EQUILIBRIA CAPITAL MANAGEMENT LTD., ONE BERMUDIANA ROAD, HAMILTON D0 HM08
Eqc Private Markets Sac Fund Ltd-eqc Biotech Sely I Fund	10 percent owner	C/O EQUILIBRIA CAPITAL MANAGEMENT LTD., ONE BERMUDIANA ROAD, HAMILTON D0 HM08
Equilibria Capital Management Ltd	10 percent owner	O'HARA HOUSE, ONE BERMUDIANA ROAD, HAMILTON D0 HM08
Eqc Private Markets Ii Sac Fund Ltd-eqc Biotech Sely Iii Fund	10 percent owner	C/O EQUILIBRIA CAPITAL MANAGEMENT LTD., ONE BERMUDIANA ROAD, HAMILTON D0 HM08